ARQT - Arcutis Biotherapeutics, Inc.
IEX Last Trade
14.345
-0.225 -1.568%
Share volume: 40,988
Last Updated: Fri 27 Dec 2024 08:30:19 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$14.57
-0.23
-1.54%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-08 | 2023-02-28 | 2023-05-09 | 2023-08-08 | 2023-11-03 | 2024-02-27 | 2024-05-14 | |
| Assets | |||||||||
| Total Assets | 300.464 M | 508.914 M | 449.274 M | 379.458 M | 320.689 M | 292.959 M | 341.365 M | 478.541 M | |
| Current Assets | 295.426 M | 496.719 M | 437.406 M | 367.676 M | 308.868 M | 281.548 M | 330.431 M | 468.062 M | |
| Inventories | 0.000 | 4.307 M | 7.514 M | 8.551 M | 10.474 M | 13.913 M | 13.134 M | 13.247 M | |
| Other Current Assets | 12.024 M | 11.784 M | 10.611 M | 13.026 M | 11.591 M | 20.180 M | 18.704 M | 13.178 M | |
| Short Term Investments | 12.024 M | 11.784 M | 10.611 M | 13.026 M | 11.591 M | 20.180 M | 18.704 M | 13.178 M | |
| Total Receivables | 0.000 | 2.431 M | 8.458 M | 12.769 M | 17.207 M | 19.417 M | 25.807 M | 37.154 M | |
| Current Cash | 282.169 M | 476.963 M | 409.589 M | 332.405 M | 268.671 M | 227.113 M | 271.861 M | 403.866 M | |
| Total Non-current Assets | 5.038 M | 12.195 M | 11.868 M | 11.782 M | 11.821 M | 11.411 M | 10.934 M | 10.479 M | |
| Property Plant Equipment | 2.078 M | 1.939 M | 1.881 M | 2.070 M | 1.867 M | 1.735 M | 1.539 M | 1.369 M | |
| Other Assets | 2.960 M | 2.881 M | 2.799 M | 2.712 M | 3.142 M | 3.051 M | 2.957 M | 2.860 M | |
| Intangible Assets | 0.000 | 7.375 M | 7.188 M | 7.000 M | 6.812 M | 6.625 M | 6.438 M | 6.250 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 300.464 M | 508.914 M | 449.274 M | 379.458 M | 320.689 M | 292.959 M | 341.365 M | 478.541 M | |
| Total liabilities | 105.082 M | 238.140 M | 239.693 M | 239.726 M | 240.181 M | 246.242 M | 252.698 M | 253.599 M | |
| Total current liabilities | 27.482 M | 37.102 M | 37.807 M | 37.025 M | 36.659 M | 41.889 M | 46.668 M | 47.309 M | |
| Accounts Payable | 8.437 M | 8.666 M | 8.827 M | 12.485 M | 17.156 M | 13.179 M | 11.992 M | 12.969 M | |
| Other liabilities | 12.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 849.000 K | 306.000 K | |
| Current long term debt | 582.000 K | 639.000 K | 657.000 K | 676.000 K | 695.000 K | 715.000 K | 735.000 K | 756.000 K | |
| Long term debt | 77.588 M | 201.038 M | 201.886 M | 202.701 M | 203.522 M | 204.353 M | 205.181 M | 205.984 M | |
| Other liabilities | 12.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 849.000 K | 306.000 K | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 195.382 M | 270.774 M | 209.581 M | 139.732 M | 80.508 M | 46.717 M | 88.667 M | 224.942 M | |
| Common stock | 51.422 M | 57.092 M | 61.101 M | 61.169 M | 61.431 M | 61.727 M | 92.895 M | 111.049 M | |
| Retained earnings | -540.036 M | -647.745 M | -719.764 M | -799.864 M | -870.855 M | -915.620 M | -981.904 M | -1.017 B |